Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of “Buy” from Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have been given an average recommendation of “Buy” by the sixteen ratings firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $78.3077.

A number of analysts recently weighed in on the stock. Truist Financial assumed coverage on shares of Janux Therapeutics in a research report on Wednesday, September 10th. They set a “buy” rating and a $100.00 price target for the company. Guggenheim assumed coverage on shares of Janux Therapeutics in a research report on Wednesday, September 3rd. They set a “buy” rating and a $72.00 price target for the company. Piper Sandler assumed coverage on shares of Janux Therapeutics in a research report on Monday, August 18th. They set an “overweight” rating and a $42.00 price target for the company. Raymond James Financial assumed coverage on shares of Janux Therapeutics in a research report on Friday, July 11th. They set an “outperform” rating and a $65.00 price target for the company. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $45.00 price target on shares of Janux Therapeutics in a research report on Wednesday, September 10th.

Hedge Funds Weigh In On Janux Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. lifted its holdings in Janux Therapeutics by 7.9% in the 1st quarter. RA Capital Management L.P. now owns 11,189,693 shares of the company’s stock worth $302,122,000 after buying an additional 824,041 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in Janux Therapeutics by 19.4% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,654,574 shares of the company’s stock worth $98,673,000 after buying an additional 592,824 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Janux Therapeutics by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 2,278,660 shares of the company’s stock worth $61,524,000 after buying an additional 142,328 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Janux Therapeutics by 25.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,392,826 shares of the company’s stock worth $37,607,000 after buying an additional 282,848 shares in the last quarter. Finally, Orbimed Advisors LLC lifted its holdings in Janux Therapeutics by 59.6% in the 2nd quarter. Orbimed Advisors LLC now owns 1,210,300 shares of the company’s stock worth $27,958,000 after buying an additional 451,734 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Stock Up 6.7%

Shares of NASDAQ JANX opened at $23.23 on Monday. The firm has a fifty day moving average of $24.07 and a 200-day moving average of $25.75. Janux Therapeutics has a 52-week low of $21.73 and a 52-week high of $71.71. The stock has a market capitalization of $1.40 billion, a PE ratio of -12.91 and a beta of 2.84.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.07). Equities research analysts expect that Janux Therapeutics will post -1.38 EPS for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.